"目錄號(hào): HY-14855
Tedizolid 是一種新穎的惡唑烷酮，具有抗革蘭氏陽(yáng)性細(xì)菌的作用辐赞。
相關(guān)產(chǎn)品
G-418 disulfate-Anisomycin-Salinomycin-Avibactam sodium-Vancomycin hydrochloride-Hygromycin B-Bleomycin sulfate-Ciprofloxacin-Minocycline hydrochloride-Ampicillin sodium-Tetracycline hydrochloride-Tebipenem-Kanamycin sulfate-Solithromycin-Tunicamycin-
生物活性
Description
Tedizolid is a novel oxazolidinone with activity against Gram-positive pathogens.
In Vitro
Tedizolid (0.25 μg/mL) inhibits all 28 clinical isolates of PRSP, and is 4-fold more potent than linezolid against PRSP[1].
In Vivo
For mice infected with PSSP type III, the 100% survival rate is achieved with tedizolid phosphate at a minimum total daily dose of 10 mg/kg. Lungs of infected mice treated with tedizolid phosphate show less severe inflammation and edema, as indicated by the mean scores for inflammation and edema[1].
Clinical Trial
Los Angeles Biomedical Research Institute
Bone and Joint Infection
February 6, 2017
Phase 2
Amit.Pai-Merck Sharp & Dohme Corp.-Albany College of Pharmacy and Health Sciences
Obesity
March 2015
Phase 4
Hartford Hospital-Merck Sharp & Dohme Corp.
Diabetes-Wound Infection-Healthy Volunteers
February 23, 2016
Phase 1
Merck Sharp & Dohme Corp.
Gram-Positive Infections
March 5, 2018
Phase 1
University of Southern California-Merck Sharp & Dohme Corp.
Cystic Fibrosis
July 2015
Phase 4
Merck Sharp & Dohme Corp.
Gram-Positive Bacterial Infections
May 2, 2016
Phase 1
Cubist Pharmaceuticals LLC
Skin Diseases, Infectious-Skin Diseases, Bacterial
March 25, 2015
Phase 3
Bayer
Abscess-Cellulitis-Erysipelas-Wound Infection
January 13, 2017
Bayer-Merck Sharp & Dohme Corp.
Bacterial Infections
March 4, 2014
Phase 3
Cubist Pharmaceuticals LLC
Pneumonia
January 6, 2014
Phase 3
Merck Sharp & Dohme Corp.
Skin Diseases, Bacterial
June 2015
Phase 1
Bayer
Skin Diseases, Infectious
November 2013
Phase 3
Trius Therapeutics LLC
Healthy
April 2008
Phase 1
View MoreCollapse
References
